{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"26","upperLimit":"68.4","value":"47.2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"50"}],"units":"Participants"}],"description":"Survival curves for OS will be estimated using the Kaplan-Meier method.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive pembrolizumab IV over 30 minutes on day 1. Treatment repeats every 21 days for up to 24 months in the absence of disease progression\\* or unacceptable toxicity.\n\n\\* NOTE: Patients with confirmed disease progression may continue to receive treatment if they are otherwise clinically stable until there is an increase in tumor burden of 25% or more following initial confirmation of progression. Under exceptional circumstances, and with protocol P.I. and CITN P.I. approval, patients may receive treatment beyond 2 years.\n\nLaboratory Biomarker Analysis: Ancillary studies\n\nPembrolizumab: Given IV","id":"OG000","title":"Treatment (Pembrolizumab)"}],"paramType":"MEDIAN","reportingStatus":"POSTED","timeFrame":"Time interval between the start of treatment to death due to any cause, assessed up to 60 months.","title":"Overall Survival (OS)","type":"SECONDARY","unitOfMeasure":"months"}